Michael Kors Handbags Navy
About Matignon Technologies, Paris, France
"This next stage of financing is an important influx of capital for GlucoLight as we continue development of our OCGM device for hospitals," said Ray Krauss, Chief Executive Officer of GlucoLight Corporation. "Since our founding in 2003, GlucoLight has focused on innovation, as well as prudent and efficient use of capital. We have been able to go from concept to working prototype including initial clinical trials in the field of intended use on an initial capital raise of $7 million. We expect the next round of financing to bring us through the clinical trials process."
the acute care environment, coupled with the worldwide diabetes epidemic, we estimate the size of our near term addressable market to be at least $500 million. In the coming months, our efforts will focus on additional product refinements to our device for the acute care environment and for eventual FDA evaluation. Eventually, we will miniaturize our glucose monitoring technology and develop a consumer product that will help both Type I and Type II diabetics better manage their glucose levels, and help decrease the complications associated with this world wide illness."
BETHLEHEM, Pa. (BUSINESS WIRE) GlucoLight Corporation, a development stage company focused on blood glucose monitoring in the acute care environment, today announced the closing of a $2 million first tranche of "C" round financing, with Michael Kors Backpack Au
The GlucoLight OCGM monitor requires regulatory clearance and is not yet commercially available.
Using Optical Coherence Tomography (OCT), GlucoLight has identified specific physiological targets within the dermis that closely correlate to changes in blood glucose levels. GlucoLight's OCGM monitor samples these physiological targets every 30 seconds to track blood glucose levels to a high degree of accuracy.
Mr. Krauss concluded, "Based on Michael Kors Handbags Navy compelling data that reinforces the importance of tight glycemic control in Michael Kors Wallet Amazon
Medical Capital Advisors of Boston, MA serves as financial advisor to GlucoLight.
will help offset labor and supply costs for hospitals. In recent trials, we have been extremely pleased with the device's accuracy."
Today, GlucoLight's OCGM monitor is the only continuous, non invasive blood glucose monitor for the acute care environment that is in clinical trials.
GlucoLight's OCGM device is intended to provide an efficient method to monitor patients' glucose levels in real time, effectively reducing the time spent on traditional blood testing methods and making it easier to achieve the cost savings associated with intensive glucose control, estimated to be $2,800 per patient.
Transoma Medical Closes $13 Million in Series C Funding to Launch Implantable Wireless Monitoring Devices Noninvasive Assessment of Plaque Deposits May Help Determine a Patient's Stroke Risk
Cepheid (CPHD)'s Xpert(TM) EV Test for Enteroviral Meningitis, Run on the GeneXpert Platform, Receives FDA Clearance Sanarus Medical Inc. Secures $15 Million Round of Financing
Mr. Krauss continued, "We have developed and demonstrated a device that will provide physicians and health care workers with a product that not only provides continuous data, but Michael Kors Handbags Yellow
The financing was led by Matignon Technologies, a venture fund located in Paris, France. Ben Franklin Technology Partners of Northeastern Pennsylvania, a state funded economic development organization that links early stage companies with funding and other resources to help them prosper through innovation also participated in the round. Other individual investors participated including both current shareholders and new investors.
Matignon Investissement Gestion, created in 1996, is an independent fund management company managing 250million. Its latest fund, Matignon Technologies II, focuses predominantly on Medtech and medical services and is one of the largest European funds in the field.
GlucoLight Corporation Raises First Tranche of 8 Million C Round
Urine Test may Predict Diabetic Kidney Disease Upstream Biosciences Inc. Signs Option to Acquire Pacific Pharma Technologies Inc.
The funding from the financing will enable GlucoLight to complete the development of its optical, continuous glucose monitor (OCGM), a non invasive monitor designed for the acute care environment. The money raised in this round of financing will help fund the clinical studies leading up to an expected pivotal trial in 2008.
the second tranche expected to close in late 2Q 2007.
Blood glucose monitoring has been called "the next vital sign", linking elevated levels with complications for all patients following surgery. Intensive glucose control protocols, including the "Portland Protocol" developed by Dr. Tony Furnary, have been shown to decrease mortality and morbidity and reduce infections in post cardiac surgery patients.
GlucoLight's continuous, non invasive device is a novel approach to glucose monitoring in the acute care environment. Using optical coherence tomography (OCT), the device is able to measure blood glucose levels through a unique anatomical area in the skin that shows physiological changes that directly correlate to changes in blood glucose. The GlucoLight monitor displays real time glucose measurements with an initial single point calibration.
Michael Kors Handbags Navy
Michael Kors Bags New Collection 2018
Michael Kors Handbags Mini
New Balance Premium
New Balance Grey And Blue
Michael Kors Bags Tan
New Balance Lightweight Running Shoes
Michael Kors Handbags Sale
Michael Kors Traveler Medium
Michael Kors Hamilton Purse
Michael Kors Bags Collection
Michael Kors Jet Set Messenger
Michael Kors Purses Light Brown
Michael Kors Jet Set Phone Case Wallet
Red New Balance Trainers
New Balance Girl Shoes